Avid Bioservices Inc (CDMO)

[Big On Tarvy]

No delays or upsets.


In a recent conversation I learned:

No delays or upsets have occurred in any of the three clinical trial programs. All pre-clincial programs are on track as well.

A significant PR can be expected in August unrelated to pending HCV trial.

Regarding HCV, the Alamo and Godofsky Centers have plenty of patients for the repeat dose trial and enrollment has gone faster than expected. The Company hopes to make some qualitative remarks about repeat dose results in the PR announcing completion of enrollment, which could happen in the week after Labor Day and just prior to the Sept 11 Conference Call. Quantitative results won’t be available until Oct 30 AASLD meeting. Full 12 week follow-up data for highest dosing cohort probably will not be available by Oct 30.

Regarding HIV, Gates Foundation is working closely with Duke. The Company plans to say more about the Duke alliance in the Sept 11 CC and Oct 24 AGM, but Duke does not want to put out a PR about a project that is still in the pre-clinical stage.

Based on promising pre-clinical data, the Company is still on track to start testing Bavi in 1 or 2 new indications before year end.

That’s all I’ve got. Short conversation!